TAK-931

CDC7 serine/threonine kinase inhibitor

oral 50 mg QD, Ph. II in solid tumors compl.

from homology model pharmacophore + opt.

Sci. Adv., May 21, 2021

Takeda Pharmaceutical, Kanagawa, JP

The Takeda CDC7 serine/threonine kinase inhibitor, simurosertib (TAK-931), is the first orally active CDC7-selective inhibitor and recently had its Ph. I study results in solid tumors posted. The drug was…


 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.